XENETIC BIOSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
XENETIC BIOSCIENCES INC. - More news...
XENETIC BIOSCIENCES INC. - More news...
- Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
- Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
- Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
- Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
- Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
- Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
- Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
- Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
- Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
- Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
- Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
- Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
- Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
- Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
- Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
- Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
- Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
- Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
- Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update